Quick Snapshot — Tell Us the One-Sentence Brief

• In one sentence, what is the trial (phase, indication) and the enrollment target you need hit?
• Which milestone date feels immovable for you (e.g., first patient in, database lock, regulatory filing)? Options: First patient in (FPI), 50% enrolled, Database lock, Regulatory submission/filing, Other
• How many sites and countries are you currently planning to open to meet that target? Options: 1–5 sites, 6–15 sites, 16–50 sites, 51+ sites, Undecided
• Who on your team will be the primary day-to-day contact for startup activities, and who is the executive owner accountable for timelines?
• How confident are you, on a scale from 1–5, that your current plan will deliver the FPI on time? (1 = not confident, 5 = fully confident) Options: 1, 2, 3, 4, 5

What’s Slowing You Down When the Clock’s Ticking?

• When you picture your ideal timeline, what single assumption do you think is most likely to be wrong?
• Which of the following has historically caused the biggest startup delay for your studies? Options: Regulatory review cycles, Ethics committee approvals, Site identification/feasibility, Contracting & budgets, Investigator availability, Logistics/import of IMP, Other
• Tell us about a recent trial where startup missed the target—what happened and how long did the slip last?
• How do those delays usually affect downstream priorities (e.g., investor updates, regulatory timelines, internal resource allocation)?
• On emotionally honest terms, how frustrated or stressed is leadership about potential timeline slippage? Options: Not at all, A little concerned, Moderately stressed, Highly stressed / frequent escalations

Regulatory & Country Reality — Are We Missing Local Landmines?

• What regulatory surprises in a country or region have forced you to rebuild parts of a timeline mid-program?
• Which countries are in-scope for this study right now? Options: United States, EU/EEA, UK, Canada, Brazil/Latin America, China/Hong Kong/Taiwan, Japan/Korea, Other
• Do any target countries require local sponsor representation, local import licenses for IMP, or specific lab accreditations? Options: Local sponsor rep required, Import license required, Local lab accreditation required, No special local requirements, Unsure / need to check
• What is your estimated regulatory approval window by country today (give ranges or specific weeks/months)?
• Have you previously sought accelerated pathways (e.g., conditional approvals, rolling reviews) in any target market for this indication? How successful were they? Options: Yes — successful, Yes — partially successful, Yes — not successful, No — not attempted, Unsure
• Which regulatory interactions feel most unpredictable to you right now, and why?

Site Reality Check — Do Your Sites Exist or Do We Need to Build Them?

• How confident are you that the patient population exists at the sites you’ve considered? Options: Very confident, Somewhat confident, Uncertain, Not confident at all
• Which criteria do you absolutely require in a site (select all that apply)? Options: Prior experience in indication, Proven recruitment track record, On-site pharmacy/IMP handling, Specialized lab/imaging capabilities, English-speaking staff, Contracting history with sponsors, Other
• Have you already pre-selected sites or investigators? If yes, how many and what evidence supports their selection? Options: No pre-selection, Yes — 1–5 named, Yes — 6–15 named, Yes — 16+ named
• What obstacles do sites typically raise when you approach them for this program (e.g., competing trials, budget concerns, staffing)?
• How quickly do you need sites activated once they’re identified (average days from selection to activation)? Options: <30 days, 30–60 days, 61–90 days, 90+ days, Undecided
• What would make you lose faith in a nominated site and remove them from consideration?

Contracts, Budgets & Bureaucracy — Where Do Deals Stall?

• What’s the single most common sticking point in site contracting for your studies? Options: Budget negotiation, Indemnity/liability terms, Publication/IP clauses, Payment cadence, Regulatory paperwork, Other
• How long does contracting with an average site typically take for your team? Options: <30 days, 30–60 days, 61–120 days, 120+ days, Varies widely
• Are you open to standardized master agreements or local addenda to accelerate contracting, or is bespoke legal language mandatory? Options: Standardized master agreements preferred, Standard with local addenda acceptable, Bespoke language mandatory, Unsure / need legal input
• What budget levers are you willing to use to speed activation (e.g., higher site fees, feasibility grants, milestone bonuses)? Options: Higher per-patient fees, Feasibility grants, Milestone bonuses, Faster payment terms, Not willing to change budget, Other
• Who on your legal/finance side needs to approve site contract templates, and how quickly can they turn around reviews?

Decision Makers, Escalation & Internal Pressures — Who’s Watching Daily?

• If enrollment slips by four weeks, who will call for an explanation and who will expect remediation?
• Which stakeholders must be regularly updated on startup progress (select all that apply)? Options: VP Clinical Ops / Head of Clinical, Regulatory lead, Chief Medical Officer, Finance/Legal, Investor relations, Project management office, Other
• How do you prefer to receive escalation notices—dashboard alerts, weekly executive summaries, or immediate calls for critical variances? Options: Dashboard alerts, Weekly exec summary, Immediate calls for critical issues, Ad-hoc emails, Combination
• What internal roadblocks (resourcing, competing trials, approvals) on your side threaten startup speed, and how long would it take you to resolve them?
• Who signs off on committing additional budget or resources if a mitigation requires it?

What Would Radical Success Look Like for Startup?

• If you could freeze one startup metric today so it never slipped again, which would it be (and why)? Options: FPI date, Time-to-site-activation, Contracting lead-time, Regulatory approval time, Enrollment per site
• What are the three KPIs you want on a daily dashboard during startup?
• Would you accept a phased rollout (e.g., core countries first) to secure early enrollment, or do you require full global activation simultaneously? Options: Phased rollout acceptable, Full global activation required, Depends on countries, Undecided
• What trade-offs are you willing to make to accelerate FPI (higher cost, fewer sites, narrower eligibility, accelerated contracting)? Options: Higher cost, Fewer sites initially, Narrower eligibility, Accelerated contracting terms, None
• If we delivered FPI two months earlier than expected, what immediate downstream benefits would you show leadership or investors?

Risks You’d Like Us to Tear Down First

• Which single risk, if it materializes, would you consider program-threatening?
• For the top three risks you identify, how have you previously tried to mitigate them and what was missing?
• Which of these contingency approaches would you prefer we prioritize (select up to two)? Options: Parallel site identification, Pre-negotiated contracting templates, Regulatory dossier pre-submission reviews, Local CRO partnerships, Feasibility patient mapping, Other
• How much buffer (in weeks) do you have in the overall program timeline before a delay would jeopardize regulatory or commercial milestones? Options: No buffer, 1–4 weeks, 5–12 weeks, 12+ weeks, Undecided
• Are there any hard-stop constraints we must respect (e.g., recruitment window tied to seasonality, expiry of product supply, investor reporting)?

Immediate Next Steps — If We Start Tomorrow, What Must Happen in 30 Days?

• Are you ready to share the protocol, Investigator Brochure, and any prior feasibility data within five business days? Options: Yes — ready to share, Yes — with NDAs/agreements, No — need internal approvals, Unsure
• Which of these kick-off actions would you most value us owning in the first 30 days (pick up to two)? Options: Regulatory gap analysis, Rapid site feasibility sweeps, Drafting contracting templates, Local lab capability checks, Stakeholder governance setup
• How do you prefer to measure progress in the first month—milestones met, risk reduction, or resource mobilization? Options: Milestones met, Risk reduction, Resource mobilization, All three
• Who needs to be on the initial governance call and what cadence would make you feel confident (weekly, twice-weekly, biweekly)? Options: Weekly, Twice-weekly, Biweekly, Monthly
• Realistically, when can you make a go/no-go decision to proceed with a CRO-led startup plan? Options: Immediately, Within 1–2 weeks, Within 3–4 weeks, Longer than a month, Unsure

• Current-State Diagnosis Workshop
• Failure Modes & Risk Mapping
• Solution Experience — Protocol-to-First-Patient Walkthrough
• Site Network Simulation & Feasibility Sprint
• Validation & Mutual Next Steps

• Identify resource gaps and confirm how sequencing changes compress timelines across sites.
• Owners for top risks to prepare one-slide summary of control options and expected delta-to-first-patient-enrolled.
• Confirm Future-State Statement
• Prove, with scenario-specific evidence, measurable time or risk reduction for each prioritized failure mode.
• Obtain explicit customer validation at each checkpoint that the proposed approach addresses their described problems.
• Agree on which scenario(s) will be used for a pilot or detailed scope development.
• Host to deliver a scenario-specific timeline comparison (current vs. proposed) showing weeks saved and owners.
• Customer to confirm scenario selections and nominate pilot sites or countries.
• Host to attach portal screenshots and relevant case-study evidence mapped to each mitigation claim.
• Review Priority Site Profiles
• Produce validated, site-specific activation plans and critical-path owners for priority sites.
• Agree measurable acceptance criteria that define the future-state site readiness.
• Introductions & Objectives
• Assign site activation leads and document O365/portal owners for each priority site.
• Host to produce a Gantt-style activation schedule per site showing parallelization and expected FPE date.
• Customer to confirm site contacts and provide outstanding documents required for activation simulations.
• Recap Validated Future-State & Metrics
• Customer explicitly accepts the proposed future-state metrics and pilot/scope or identifies required adjustments.
• Decision to proceed to a pilot or to develop a detailed Solution Scope with agreed owners and dates.
• Establish governance owners and immediate action items to move into execution.
• Host to draft a one-page Pilot Proposal (scope, sites, success metrics, timeline, high-level commercial terms) and circulate within 3 business days.
• Customer to confirm pilot approval and sign-off authorities or provide required edits to scope.
• Schedule Solution Scope kickoff meeting with regulatory, contracting, and site ops leads and provide required pre-reads.
• Agree on one precise current-state sentence that all parties can repeat.
• Quantify at least three concrete consequences (time, cost, regulatory) tied to the current-state.
• Confirm decision-makers, timelines, and data required for the next meeting (protocol, site lists, historical startup metrics).
• Customer to provide final protocol, target site list, and historical startup metrics (timelines, common delays) before the next meeting.
• Host to draft the agreed one-sentence current-state and consequence summary and circulate for confirmation.
• Schedule Failure Modes & Risk Mapping session and list required attendees (regulatory, ops, contracting leads).
• Recap Current-State & Consequences
• A prioritized list of failure modes with root causes and quantified consequence scores.
• Clear set of proof artifacts and data required to demonstrate mitigation effectiveness in later sessions.
• Assigned owners for each top-priority failure mode who will support the Solution Experience demo.
• Sponsor to share examples of recent failure incidents (redacted) and timelines for root-cause review.
• Host to assemble historical CRO performance cases and internal mitigation playbooks mapped to prioritized failure modes.
• One-Sentence Current-State
• Simulated Activation — Site A
• Select Two Customer Scenarios
• Identify Failure Modes by Domain
• Review Evidence & Scenario Outcomes
• Agree Pilot/Scope & Acceptance Criteria
• Scenario Walkthrough — Regulatory Path & Submission
• Simulated Activation — Site B
• Root-Cause & Frequency Assessment
• Protocol & Site Data Review
• Consequence Quantification
• Resource & Sequence Optimization
• Consequence Scoring & Prioritization
• Operational & Commercial Prerequisites
• Scenario Walkthrough — Site Activation Sequence
• Portal & Milestone Proof
• Decision, Owners & Next Meetings
• Decision-Maker & Timeline Alignment
• Data Requirements for Proofs
• Acceptance Criteria for Site Readiness
• Validation & Next Meeting Prep
• Validation Checkpoints

• Prepare and file regulatory submission dossiers
• Submit and manage ethics committee applications
• Translate and notarize informed consent forms
• Conduct site qualification visits (on-site or virtual)
• Execute site contracts and budgets
• Deliver investigator and coordinator training sessions
• Distribute study start-up documents and investigator packs
• Populate and maintain real-time startup milestone portal
• Coordinate central lab kit and sample logistics
• Manage investigational product shipment to sites
• Obtain site regulatory approvals and local import permits
• Upload and index documents into eTMF

Prepare and file regulatory submission dossiers

• Which countries or regulatory regions require a formal dossier submission for this study? Options: United States (FDA), European Union (EMA/NCAs), United Kingdom (MHRA), Canada (Health Canada), China (NMPA), Japan (PMDA), Other (please list)
• What type(s) of regulatory submissions are needed for initial filing and maintenance? Options: Investigational New Drug / CTA/IND, Clinical Trial Notification, National ethics/regulatory filing, Device-specific submission, Regulatory amendments only, Other (please specify)
• Who will be the primary dossier owner and signatory (Sponsor, CRO, local representative)? Options: Sponsor, CRO, Local Regulatory Agent/Representative, Co-sponsor/Partner, Undecided
• Are there pre-submission meetings or scientific advice expected with any authority? Options: Yes, No
• What is the target date for initial regulatory submission (or earliest acceptable submission window)?
• Are regulatory documents required in local languages or with certified translations/notarizations? Options: Yes, No, Partially/Some countries only

Submit and manage ethics committee applications

• Will you require a submission to a single central ethics committee or multiple local IRBs/ECs? Options: Central/Single EC, Multiple local ECs, Combination (central + local)
• How many distinct ethics committees/IRBs do you anticipate submitting to? Options: 1, 2-5, 6-15, 16+
• Do any sites have specialist committees (pediatrics, oncology, device safety) or expedited review pathways? Options: Yes, No, Unknown
• Who will prepare the ethics application package (Sponsor, CRO, local site, hybrid)? Options: Sponsor, CRO, Local Site/PI, Hybrid - responsibilities split
• Are there institutional or country-specific consent/assent requirements or templates to follow? Options: Yes, No, Partially
• What target review timelines should we plan for initial EC/IRB approvals in key countries?

Translate and notarize informed consent forms

• Which local languages will informed consent forms (ICFs) need to be translated into?
• Do you require certified translations and/or notarization/legalization for any country? Options: Certified translation, Notarization, Apostille/legalization, None required, Unknown
• Will you use a standard Sponsor ICF template or site-specific consent wording? Options: Sponsor template, Site-specific templates required, Hybrid/negotiable
• Are electronic consent (eConsent) options acceptable at your sites or is wet signature required? Options: eConsent accepted, Wet signature only, Depends on country/site
• How many distinct ICF versions are expected (by cohort, language, sub-study)? Options: 1, 2-5, 6-15, 16+
• Please list any culturally sensitive content or local regulatory clauses that must be included in translations.

Conduct site qualification visits (on-site or virtual)

• How many sites require qualification visits for this study? Options: 1-5, 6-20, 21-50, 50+
• Which visit modalities are acceptable (on-site, virtual, hybrid)? Options: On-site, Virtual (tele-visit), Hybrid (initial on-site then virtual)
• What minimum checklist items must be evaluated during qualification (facilities, equipment, staff experience, lab capabilities)?
• Are site access, travel restrictions, or PPE/COVID policies likely to affect on-site visits? Options: Yes, No, Unknown
• Who will be required to attend (PI, study coordinator, pharmacist, lab lead)? Options: Principal Investigator, Study Coordinator, Pharmacist, Lab Lead/Technologist, Other (specify)
• Is photographic or video evidence of facilities required for remote qualification? Options: Yes, No, Optional

Execute site contracts and budgets

• How many site contracts are anticipated and across how many legal jurisdictions? Options: 1-5, 6-20, 21-50, 50+
• Will you use a Sponsor master agreement, template CRO agreement, or site-negotiated contracts? Options: Sponsor master template, CRO template, Site-negotiated, Hybrid
• What are preferred payment terms and currency requirements? Options: Net 30, Net 45, Milestone-based, Per-patient, Local currency required
• Are there country-specific taxation, invoicing, or banking requirements we should plan for? Options: Yes, No, Unknown
• Do you require central negotiation or we should engage local legal counsel for each jurisdiction? Options: Central negotiation only, Engage local legal counsel, Mix by country
• What is your target turnaround time for fully executed site contracts? Options: <2 weeks, 2-4 weeks, 4-8 weeks, 8+ weeks

Deliver investigator and coordinator training sessions

• Which formats do you prefer for training delivery? Options: In-person classroom, Live webinar, On-demand eLearning, Blended (train-the-trainer)
• How many training sessions per site or region are needed to cover protocol and site procedures? Options: 1, 2-3, 4-6, More than 6
• Do you require certifications, attendance rosters, and quizzes recorded in the portal? Options: Yes, No, Partial (e.g., only PIs)
• Will training need translation or simultaneous interpretation for local teams? Options: Yes, No, Some languages
• Should training include site-specific SOPs (pharmacy, lab, consent) or only protocol-level content? Options: Protocol-level only, Protocol + site SOPs, Custom per site
• Do you want post-training competency assessments and corrective action tracking? Options: Yes, No

Distribute study start-up documents and investigator packs

• Which documents must be included in each investigator pack (e.g., protocol, ICF, lab manual, IMP accountability log)?
• How will documents be distributed: secure portal, courier, email, or mixed? Options: Secure portal, Courier (physical), Email, Mixed
• Are there version control or signed distribution acknowledgement requirements for investigators? Options: Yes, signed acknowledgement, Version-controlled portal only, No formal requirement
• Do any sites require sealed or temperature-controlled investigator kits or materials? Options: Yes, No, Not applicable
• What is the expected timeline between final document approval and investigator pack distribution? Options: <48 hours, 3-7 days, 1-2 weeks, More than 2 weeks
• Are there local regulatory requirements for providing paper vs electronic investigator packs? Options: Paper required, Electronic acceptable, Depends on country/site

Populate and maintain real-time startup milestone portal

• Which stakeholders need access to the portal (Sponsor CRA, Site staff, Executive team, Lab, Regulatory)? Options: Sponsor CRAs, Site staff, Sponsor Executive team, CRO operational leads, Central lab, Other (specify)
• Which KPIs should be tracked in real time (site activation date, EC approval, contract signed, first patient in)? Options: Site activation, EC/IRB approval, Contract execution, Regulatory approval, First patient enrolled, Other (specify)
• Do you require integration between the portal and sponsor systems (eTMF, CTMS, EDC)? Options: Yes - eTMF, Yes - CTMS, Yes - EDC, No integrations, Other
• How frequently should milestone statuses be updated (real-time, daily, weekly)? Options: Real-time/auto, Daily, Weekly, As-needed on milestone change
• What notification and escalation preferences do you want for missed milestones or delays? Options: Email alerts, SMS/Push, Dashboard flags only, Escalate to Sponsor lead
• Do you need downloadable reports or custom dashboards for executive reporting? Options: Yes - downloadable, Yes - custom dashboards, No

Coordinate central lab kit and sample logistics

• Which central lab(s) will be used and are they local or regional hubs?
• What types of kits are required (blood, urine, swabs, specialized tubes) and any stability/temperature constraints?
• Will kits be shipped directly to sites or via regional depots? Options: Direct-to-site, Regional depot, Hybrid
• Are import/export permits or customs clearance required for sample/kits in any country? Options: Yes, No, Unknown
• Do you require chain-of-custody tracking, barcoding, and electronic sample manifest integration? Options: Yes - full tracking, Partial tracking, No
• What is the expected frequency of kit replenishment and sample pick-ups per site? Options: Weekly, Bi-weekly, Monthly, Per visit/on-demand

Manage investigational product shipment to sites

• What are the IMP storage and transport conditions (ambient, refrigerated, frozen, controlled temperature)? Options: Ambient, Refrigerated (2-8°C), Frozen (-20°C/-80°C), Controlled temperature packs
• Will IMP be shipped direct-to-site or via central depots/wholesalers? Options: Direct-to-site, Via central depot, Combination
• Are local import permits, controlled substance licenses, or customs brokerage required? Options: Yes - import permits, Yes - controlled substance license, Yes - customs brokerage, No
• Who handles randomization/blinding and kit labeling - Sponsor, CRO, or depot? Options: Sponsor, CRO, Depot/blinding service, Other
• Do sites require pharmacist-led receipt and accountability training and documentation? Options: Yes, No, Some sites only
• Please estimate the number of initial and recurring IMP shipments per site. Options: 1-2 initial + recurring, 3-6, 7-12, More than 12

• Non-Disclosure Agreement (NDA)
• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Service Level Agreement (SLA) — Startup Timelines
• Pricing & Payment Schedule
• Data Processing & Access Agreement (DPA)
• Regulatory Responsibilities & Submission Agreement
• Governance Charter & Escalation Matrix
• Site Contracting & Budgeting Framework
• Acceptance Criteria & KPI Sign-off
• Change Order & Scope Management Process
• Compliance Assurance & Audit Rights
• Intellectual Property & Publication Agreement
• Termination & Exit Plan

• First-Patient-Enrolled (FPE) Confirmation & KPI Validation
• Lessons Learned Retrospective — Startup Phase
• Backlog Grooming & Prioritization — Startup Improvements
• Post-Activation Site Recovery & Optimization
• Executive Outcome & Startup Closeout Review

• Create site-level intervention tasks in the portal with owners, dates, and success metrics.
• Plan a short training refresh for sites or internal teams if procedural gaps were identified.
• Review Open Backlog Snapshot
• Have a prioritized backlog with clear owners and committed timelines for highest-impact items.
• Ensure acceptance criteria and dependencies are defined for top items to avoid rework.
• Create a delivery plan for items to be implemented in the next improvement cycle.
• Enter/Update prioritized items in the backlog tool with owner, priority, and acceptance criteria.
• Schedule resource assignments and block calendar time for delivery sprints.
• Communicate backlog priorities and expected delivery dates to sponsor stakeholders.
• Underperforming Site Dashboard
• Agree a tailored remediation plan for each underperforming site with owners and timelines.
• Ensure resource commitments (CRO/sponsor/local) are in place to execute interventions.
• Define escalation triggers and checkpoint cadence to monitor progress.
• Welcome & Objectives
• Schedule site follow-up calls and monitoring visits as required.
• Update sponsor on expected incremental enrollment from interventions and revised timelines.
• Executive Summary: FPE & KPI Outcomes
• Obtain formal executive sign-off on startup completion and FPE confirmation.
• Resolve SLA/commercial implications or agree remediation steps.
• Agree and schedule delivery of final closeout package and transition plan.
• Confirm ongoing governance cadence for enrollment monitoring.
• Distribute the formal closeout package (FPE evidence, KPI report, lessons learned summary) to executive stakeholders.
• Finalize any financial reconciliations and issue/resolve invoices or credits.
• Document executive approvals in contract repository and update trial status to 'Startup Closed'.
• Schedule recurring enrollment governance meetings and handover materials to operations team.
• Formally verify and document first-patient-enrolled with source evidence.
• Validate the accuracy of startup KPIs and identify any data issues.
• Agree on acceptance or list of corrective actions required to close the startup phase.
• Assign owners and timelines for any outstanding mitigations and follow-ups.
• Publish FPE confirmation record in the trial portal with attached source documents.
• Correct and re-publish KPI dashboard data where discrepancies were identified.
• Create and assign corrective action tasks for each non-conforming KPI or at-risk site.
• Schedule verification checkpoint within X days to confirm remediation progress.
• Context & Timeline Recap
• Capture a complete, evidence-backed list of lessons learned from startup.
• Produce a prioritized list of improvements with clear owners and acceptance criteria.
• Agree a timeline and owner for updating SOPs, templates, and training materials.
• Create initial backlog items ready for grooming and scheduling.
• Publish the lessons learned report with supporting evidence and distribution list.
• Create prioritized backlog entries in the shared system and assign owners.
• Assign owner to update affected SOPs/templates and set target completion dates.
• Site-Level Cause Analysis
• SLA & Commercial Performance
• What Went Well
• FPE Evidence Review
• Triage & Re-Prioritize
• Define Acceptance Criteria & Dependencies
• KPI Dashboard Validation
• Financial Reconciliation
• Intervention Design
• What Didn't Go Well — Root Cause Analysis
• Variance and Root Cause Summary
• Resource & Timeline Commitments
• Improvement Opportunities & Prioritization
• Owner Assignment & Timeline Commitments
• Governance & Outstanding Disputes
• Closeout Deliverables & Sign-Offs
• Open Risks & Mitigations
• Release/Deployment Planning
• Action Backlog Drafting